NDA 220934 · Eli Lilly and CO
Foundayo
Orforglipron Calcium · Oral
NovelCDER novel approval, Apr 1, 2026: To reduce excess body weight and maintain weight reduction long term in adults with obesity or adults with overweight in the presence of at least one weight-related comorbid condition, in combination with a reduced-calorie diet and increased physical activity
Last checked: Nov 20, 2026Latest source record: Aug 4, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2026
Apr 1, 2026
Approved uses
1
Original approval plus efficacy supplements
Registered trials
53
27 Phase 3, 10 recruiting
FAERS reports
3,056
138 serious, 4 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
Boxed warning
WARNING: RISK OF THYROID C-CELL TUMORS In products with glucagon-like peptide-1 (GLP-1) receptor agonist activity that are pharmacologically active in rats and mice, rodent thyroid C-cell tumors (adenomas and carcinomas) have been observed at clinically relevant exposures and are considered GLP-1 receptor-dependent effects in rodents. Orforglipron is not pharmacologically active in rats or mice and did not produce tumors in rodents [see Nonclinical Toxicology ( 13.1 )] . While orforglipron is pharmacologically active at the human GLP-1 receptor, the human relevance of GLP-1 receptor-dependent thyroid C-cell tumors observed in rodents has not been determined [see Warnings and Precautions ( 5.1 ), Nonclinical Toxicology ( 13.1 )] . FOUNDAYO is contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or in patients with Multiple Endocrine Neoplasia...
What it is approved for
From the label in effect Jul 29, 2026.
FOUNDAYO TM is indicated in combination with a reduced-calorie diet and increased physical activity to reduce excess body weight and maintain weight reduction long term in adults with obesity or adults with overweight in the presence of at least one weight-related comorbid condition. FOUNDAYO™ is a GLP-1 receptor agonist indicated in combination with a reduced-calorie diet and increased physical activity to reduce excess body weight and maintain weight reduction long term in adults with obesity or adults with overweight in the presence of at least one weight-related comorbid condition. ( 1 ) Limitations of Use Concomitant use with another GLP-1 receptor agonist is not recommended. ( 1 ) Limitations of Use Concomitant use with another GLP-1 receptor agonist is not recommended.
Mechanism: FOUNDAYO is a GLP-1 receptor agonist that binds to and activates the human GLP-1 receptor. GLP-1 is a physiological regulator of appetite and caloric intake. GLP-1 receptors are present in brain regions that regulate appetite. In animal studies, orforglipron distributed to and activated neurons in brain regions that regulate appetite and food intake.
Therapeutic areas: Cardiovascular and metabolic
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
6 products under this application
- FOUNDAYO · ORFORGLIPRON CALCIUM EQ 2.5MG BASE · TABLET, ORAL · Prescription
- FOUNDAYO · ORFORGLIPRON CALCIUM EQ 14.5MG BASE · TABLET, ORAL · Prescription
- FOUNDAYO · ORFORGLIPRON CALCIUM EQ 5.5MG BASE · TABLET, ORAL · Prescription
- FOUNDAYO · ORFORGLIPRON CALCIUM EQ 0.8MG BASE · TABLET, ORAL · Prescription
- FOUNDAYO · ORFORGLIPRON CALCIUM EQ 17.2MG BASE · TABLET, ORAL · Prescription
- FOUNDAYO · ORFORGLIPRON CALCIUM EQ 9MG BASE · TABLET, ORAL · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Orforglipron" as an intervention, any sponsor and status, largest first.
- A Study of Orforglipron (LY3502970) on Cardiovascular Outcomes in Adults With Atherosclerotic Cardiovascular Disease and/or Chronic Kidney Disease (ATTAIN-Outcomes)Pivotal-lookingRecruiting
Eli Lilly and CompanyEli Lilly (LLY)
NCT07241390 · 7,140 participants (planned) · Start Dec 1, 2025 · Primary completion Aug 2031
Drug: Orforglipron; Placebo · For: Atherosclerosis Cardiovascular Disease; Chronic Kidney Disease
Sites: Bahía Blanca, Argentina; Buenos Aires, Argentina; C.a.b.a., Argentina · 566 sites in all
- A Study of Orforglipron (LY3502970) in Adult Participants With Obesity or Overweight With Weight-Related ComorbiditiesPivotal-lookingActive, not recruiting
Eli Lilly and CompanyEli Lilly (LLY)
NCT05869903 · 3,127 participants · Start Jun 5, 2023 · Primary completion Jul 25, 2025
Drug: Orforglipron; Placebo · For: Obesity; Overweight; Overweight or Obesity
Sites: Chandler, Arizona; Sun City West, Arizona; Concord, California · 138 sites in all
- A Study of Daily Oral Orforglipron (LY3502970) Compared With Insulin Glargine in Participants With Type 2 Diabetes and Obesity or Overweight at Increased Cardiovascular RiskPivotal-lookingCompleted
Eli Lilly and CompanyEli Lilly (LLY)
NCT05803421 · 2,749 participants · Start Apr 3, 2023 · Primary completion Mar 16, 2026
Drug: Orforglipron; Insulin Glargine · For: Type 2 Diabetes; Obesity; Overweight or Obesity and 3 more
Sites: Daphne, Alabama; Mobile, Alabama; Pelham, Alabama · 358 sites in all
- A Study of Orforglipron in Participants With Overweight at Risk of Development of Obesity-Related Complications or Progression to Class 1 ObesityPivotal-lookingRecruiting
Eli Lilly and CompanyEli Lilly (LLY)
NCT07794579 · 2,001 participants (planned) · Start Aug 26, 2026 · Primary completion Aug 2029
Drug: Orforglipron; Placebo · For: Overweight; Prediabetic State; Prehypertension and 1 more
Sites: Anniston, Alabama; Birmingham, Alabama; Pelham, Alabama · 180 sites in all
- A Study of Orforglipron (LY3502970) Compared With Semaglutide in Participants With Type 2 Diabetes Inadequately Controlled With MetforminPivotal-lookingCompleted
Eli Lilly and CompanyEli Lilly (LLY)
NCT06045221 · 1,698 participants · Start Sep 22, 2023 · Primary completion Aug 22, 2025
Drug: Orforglipron; Semaglutide · For: Type 2 Diabetes
Sites: Phoenix, Arizona; Canoga Park, California; Escondido, California · 131 sites in all
- A Study of Orforglipron in Adult Participants With Obesity or Overweight and Type 2 DiabetesPivotal-lookingCompleted
Eli Lilly and CompanyEli Lilly (LLY)
NCT05872620 · 1,613 participants · Start Jun 5, 2023 · Primary completion Aug 8, 2025
Drug: Orforglipron; Placebo · For: Obesity; Overweight; Type 2 Diabetes
Sites: Pelham, Alabama; Tucson, Arizona; Yuma, Arizona · 136 sites in all
- A Master Protocol for Orforglipron (LY3502970) in Participants With Obesity or Overweight With and Without Type 2 DiabetesPivotal-lookingActive, not recruiting
Eli Lilly and CompanyEli Lilly (LLY)
NCT06993792 · 1,400 participants (planned) · Start May 15, 2025 · Primary completion Aug 2027
Drug: Orforglipron; Placebo · For: Obesity; Overweight; Type 2 Diabetes
Sites: Sun City West, Arizona; Tucson, Arizona; San Ramon, California · 80 sites in all
- Efficacy and Safety of Orforglipron in Participants With Peripheral Artery DiseasePivotal-lookingRecruiting
Eli Lilly and CompanyEli Lilly (LLY)
NCT07223593 · 1,205 participants (planned) · Start Oct 31, 2025 · Primary completion Jun 2028
Drug: Orforglipron; Placebo · For: Peripheral Arterial Disease
Sites: Birmingham, Alabama; Gilbert, Arizona; Surprise, Arizona · 169 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- nausea717
- drug ineffective551
- constipation331
- vomiting282
- weight increased246
- fatigue227
- weight loss poor218
- diarrhoea212
- headache187
- illness147
- abdominal pain upper137
- dizziness130
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2025 | 1 |
| 2026 | 3,055 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment.
Wharton S, Aronne LJ, Stefanski A, et al. · N Engl J Med 2025 · Randomized Controlled Trial, Multicenter Study
- Orforglipron Added to Titrated Insulin Glargine in Type 2 Diabetes: The ACHIEVE-5 Randomized Clinical Trial.
Giorgino F, D'Souza S, Ludwig L, et al. · JAMA 2026 · Randomized Controlled Trial, Multicenter Study
- Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist, in Early Type 2 Diabetes.
Rosenstock J, Hsia S, Nevarez Ruiz L, et al. · N Engl J Med 2025 · Randomized Controlled Trial, Clinical Trial, Phase III
- Emerging pharmacotherapies for obesity: A systematic review.
Kokkorakis M, Chakhtoura M, Rhayem C, et al. · Pharmacol Rev 2025 · Systematic Review
- Medications for adults with type 2 diabetes: a living systematic review and network meta-analysis.
Nong K, Jeppesen BT, Shi Q, et al. · BMJ 2025 · Systematic Review, Network Meta-Analysis
- Seven glucagon-like peptide-1 receptor agonists and polyagonists for weight loss in patients with obesity or overweight: an updated systematic review and network meta-analysis of randomized controlled trials.
Xie Z, Zheng G, Liang Z, et al. · Metabolism 2024 · Systematic Review, Network Meta-Analysis
Sponsor: Eli Lilly
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.